Emergent Biosolutions, Inc. (EBS): Price and Financial Metrics
Emergent Biosolutions, Inc. (EBS)
Today's Latest Price: $89.97 USD
Updated Oct 30 7:00pm
Add EBS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
EBS Stock Summary
- Emergent BioSolutions Inc's market capitalization of $4,761,652,263 is ahead of 77.4% of US-listed equities.
- Over the past twelve months, EBS has reported earnings growth of -660,600%, putting it ahead of just 0% of US stocks in our set.
- As for revenue growth, note that EBS's revenue has grown 43.4% over the past 12 months; that beats the revenue growth of 88.54% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Emergent BioSolutions Inc are PPSI, RAD, SYNA, QGEN, and RCM.
- EBS's SEC filings can be seen here. And to visit Emergent BioSolutions Inc's official web site, go to www.emergentbiosolutions.com.
EBS Stock Price Chart Interactive Chart >
EBS Price/Volume Stats
| Current price | $89.97 | 52-week high | $137.61 |
| Prev. close | $90.77 | 52-week low | $46.37 |
| Day low | $88.45 | Volume | 405,794 |
| Day high | $91.03 | Avg. volume | 648,991 |
| 50-day MA | $104.29 | Dividend yield | N/A |
| 200-day MA | $83.79 | Market Cap | 4.76B |
Emergent Biosolutions, Inc. (EBS) Company Bio
Emergent BioSolutions is a biopharmaceutical company which develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company was founded in 1998 and is based in Gaithersburg, Maryland.
EBS Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $89.97 | $67.98 | -26% |
We started the process of determining a valid price forecast for Emergent BioSolutions Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Emergent BioSolutions Inc ranked in the 38th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for EBS, they are:
- Emergent BioSolutions Inc's effective tax rate, as measured by taxes paid relative to net income, is at 18 -- greater than 74.15% of US stocks with positive free cash flow.
- Emergent BioSolutions Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at 7.68. This coverage rate is greater than that of 73.15% of stocks we're observing for the purpose of forecasting via discounted cash flows.
- The weighted average cost of capital for the company is 8. This value is greater than only 23.92% stocks in the Healthcare sector that generate free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -27% |
| 1% | -26% |
| 2% | -26% |
| 3% | -25% |
| 4% | -24% |
| 5% | -23% |
Want more companies with a valuation profile/forecast similar to that of Emergent BioSolutions Inc? See ICLR, NVS, STE, BDX, and RSCF.
Loading social stream, please wait...